Synergistic Oncolytic Virus Systems for Personalized Cancer Treatment

This invention integrates oncolytic viruses with improved safety and anticancer effect with distinct technologies such as AI, IoT, blockchain, and new materials to create a more powerful system for personalized cancer treatment.

The original patent disclosed an oncolytic virus with improved safety and anticancer effect. However, there was a need to further enhance the virus's efficacy and safety by leveraging advancements in AI, IoT, blockchain, and new materials. This inventive concept addresses this limitation by combining the oncolytic virus with these technologies to create a synergistic system.

The inventive concept comprises a system for personalized cancer treatment, wherein the oncolytic virus is administered in combination with a machine learning-based diagnostic tool to identify optimal treatment regimens for individual patients. Additionally, the system integrates a blockchain-based platform to securely store and share genetic information of the virus, and an IoT-enabled device for real-time monitoring of virus efficacy and toxicity in patients. Furthermore, the system utilizes AI-powered analysis to predict optimal virus variants and a nanomaterial-based delivery system to enhance tumor specificity and reduce systemic toxicity.

The new claims introduce a synergistic combination of the oncolytic virus with AI, IoT, blockchain, and new materials, which is not obvious from the original patent. The integration of these technologies enables a more effective and personalized cancer treatment approach.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the system could be adapted for use with other types of viruses or cancer therapies.

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the area of personalized medicine. The system's ability to provide targeted and effective treatment regimens could lead to improved patient outcomes and reduced healthcare costs.